Perera Molligoda Arachchige Arosh S, Dashiell Anna, Jesuraj Anton Shiraan, D'Urso Antonia Immacolata, Fiore Benedetta, Cattaneo Martina, Pierzynska Emilia, Szydelko Sandra, Centini Francesca Romana, Verma Yash
Emergency Service, GHOL-Hopital de Nyon, Nyon 1260, Vaud, Switzerland.
Faculty of Medicine, Humanitas University, Pieve Emanuele 20072, Lombardy, Italy.
World J Radiol. 2025 Aug 28;17(8):107732. doi: 10.4329/wjr.v17.i8.107732.
Photon-counting detector (PCD) CT represents a transformative advancement in radiological imaging, offering superior spatial resolution, enhanced contrast-to-noise ratio, and reduced radiation dose compared with the conventional energy-integrating detector CT.
To evaluate PCD CT in oncologic imaging, focusing on its role in tumor detection, staging, and treatment response assessment.
We performed a systematic PubMed search from January 1, 2017 to December 31, 2024, using the keywords "photon-counting CT", "cancer", and "tumor" to identify studies on its use in oncologic imaging. We included experimental studies on humans or human phantoms and excluded reviews, commentaries, editorials, non-English, animal, and non-experimental studies. Study selection followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Out of 175 initial studies, 39 met the inclusion criteria after screening and full-text review. Data extraction focused on study type, country of origin, and oncologic applications of photon-counting CT. No formal risk of bias assessment was performed, and the review was not registered in PROSPERO as it did not include a meta-analysis.
Key findings highlighted the advantages of PCD CT in imaging renal masses, adrenal adenomas, ovarian cancer, breast cancer, prostate cancer, pancreatic tumors, hepatocellular carcinoma, metastases, multiple myeloma, and lung cancer. Additionally, PCD CT has demonstrated improved lesion characterization and enhanced diagnostic accuracy in oncology. Despite its promising capabilities challenges related to data processing, storage, and accessibility remain.
As PCD CT technology evolves, its integration into routine oncologic imaging has the potential to significantly enhance cancer diagnosis and patient management.
光子计数探测器（PCD）CT代表了放射成像领域的一项变革性进展，与传统的能量积分探测器CT相比，它具有卓越的空间分辨率、更高的对比度噪声比以及更低的辐射剂量。
评估PCD CT在肿瘤成像中的应用，重点关注其在肿瘤检测、分期和治疗反应评估中的作用。
我们于2017年1月1日至2024年12月31日在PubMed上进行了系统检索，使用关键词“光子计数CT”、“癌症”和“肿瘤”来识别关于其在肿瘤成像中应用的研究。我们纳入了对人类或人体模型的实验研究，排除了综述、评论、社论、非英文研究、动物研究和非实验研究。研究选择遵循系统评价和Meta分析的首选报告项目指南。在175项初始研究中，经过筛选和全文审查，有39项符合纳入标准。数据提取重点关注研究类型、原产国以及光子计数CT的肿瘤学应用。未进行正式的偏倚风险评估，且该综述未在PROSPERO中注册，因为它不包括Meta分析。
主要发现突出了PCD CT在肾肿块、肾上腺腺瘤、卵巢癌、乳腺癌、前列腺癌、胰腺肿瘤、肝细胞癌、转移瘤、多发性骨髓瘤和肺癌成像中的优势。此外，PCD CT在肿瘤学中已显示出改善病变特征和提高诊断准确性的效果。尽管其功能前景广阔，但与数据处理、存储和可及性相关的挑战仍然存在。
随着PCD CT技术的发展，将其整合到常规肿瘤成像中有可能显著提高癌症诊断和患者管理水平。
